Search
Glembatumumab vedotin
go.drugbank.com/drugs/DB05996InvestigationalA conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer.
Cimicoxib
go.drugbank.com/drugs/DB05095InvestigationalIf approved, Cimicoxib would be the first drug in decades to treat depression by a new mechanism of action. … Cimicoxib is a selective COX-2 inhibitor being developed by Affectis as a treatment for depression and schizophrenia.
R-348
go.drugbank.com/drugs/DB06321InvestigationalSynonyms: 5-Fluoro-N-(4-methyl-3-propionylaminosulfonylphenyl)-N'-(4-(prop-2-ynyloxy)phenyl)-2,4-pyrimidinediamineImazaquin
go.drugbank.com/drugs/DB04582ExperimentalCategories: Compounds used in a research, industrial, or household setting2,5-di-tert-butylhydroquinone
go.drugbank.com/drugs/DB04638ExperimentalCategories: Compounds used in a research, industrial, or household settingZanapezil
go.drugbank.com/drugs/DB04859ExperimentalZanapezil (TAK-147) is a selective acetylcholine (ACh) esterase inhibitor under investigation as a drug for Alzheimer's disease (AD) treatment.
LY2275796
go.drugbank.com/drugs/DB05165InvestigationalLY2275796 targets eukaryotic initiation factor- 4E (eIF-4E), a protein involved in the translation of key growth and survival factors that drive tumor progression, angiogenesis and metastases. … LY2275796 is a second-generation antisense anti-cancer drug candidate for clinical development.
Bizelesin
go.drugbank.com/drugs/DB12352InvestigationalBizelesin has been used in trials studying the treatment of Unspecified Adult Solid Tumor, Protocol Specific.
Categories: Compounds used in a research, industrial, or household settingPhenolsulfonphthalein
go.drugbank.com/drugs/DB13212ExperimentalPhenolsulfonphthalein or otherwise called phenol red is a pH indicator commonly used in cell biology laboratories. … Phenolsulfonphthalein is being investigated for use clinically due to its weak estrogen mimicking actions [A174964].
Categories: Compounds used in a research, industrial, or household settingEfalizumab
go.drugbank.com/drugs/DB00095ApprovedWithdrawnThe FDA approved efalizumab in 2003. It was later withdrawn in 2009 due to a potential risk of progressive multifocal leukoencephalopathy (PML).[L43797] … Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin.